1068
Last Update Posted: 2021-11-04
Recruiting has ended
All Genders accepted | 12 Years + |
210 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Study of Disease Progression and Anti-HIV Treatments
To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment for 6 months.
Eligibility
Relevant conditions:
HIV Infections
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
No valid contacts available
Data sourced from ClinicalTrials.gov